{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 94,
        "end": 98
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 186,
        "end": 200
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 254,
        "end": 264
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 267,
        "end": 282
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 285,
        "end": 295
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 298,
        "end": 310
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 317,
        "end": 328
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 224,
        "end": 248
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "23679233_4",
  "text": "METHODS : Genomic alterations were analyzed using single-nucleotide polymorphism arrays in 46 HER2 immunohistochemistry ( IHC ) 3 + or 2 + / fluorescent in situ hybridization ( FISH ) + breast cancers that were treated with neoadjuvant chemotherapy with paclitaxel , cyclophosphamid , epirubicin , fluorouracil , and trastuzumab ."
}
